Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (åbner nyt vindue)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Kilde‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indekseret‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (åbner nyt vindue)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (åbner nyt vindue)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Kilde‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indekseret‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (åbner nyt vindue)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (åbner nyt vindue)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Kilde‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indekseret‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (åbner nyt vindue)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (åbner nyt vindue)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Kilde‎: Blood 2003;102(4):1529-30.

Indekseret‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (åbner nyt vindue)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (åbner nyt vindue)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Kilde‎: Transfusion 2007;47(10):1830-6.

Indekseret‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (åbner nyt vindue)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (åbner nyt vindue)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Kilde‎: Iran J Blood Cancer 2009;1(4):147-50.

Indekseret‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (åbner nyt vindue)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (åbner nyt vindue)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Kilde‎: Int J Hematol 2012;95(1):51-6.

Indekseret‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (åbner nyt vindue)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (åbner nyt vindue)

Perrine SP.

Kilde‎: Pediatr Ann 2008;37(5):339-46.

Indekseret‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (åbner nyt vindue)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (åbner nyt vindue)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Kilde‎: Sci Rep. 2022;12(1):2752.

Indekseret‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (åbner nyt vindue)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (åbner nyt vindue)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Kilde‎: Haematologica 2004;89(10):1172-8.

Indekseret‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (åbner nyt vindue)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (åbner nyt vindue)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Kilde‎: Arch Iran Med 2009;12(3):295-7.

Indekseret‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (åbner nyt vindue)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (åbner nyt vindue)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Kilde‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indekseret‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (åbner nyt vindue)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (åbner nyt vindue)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Kilde‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indekseret‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (åbner nyt vindue)

Fetal globin gene inducers: novel agents and new potential. (åbner nyt vindue)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Kilde‎: Ann N Y Acad Sci 2010;1202:158-64.

Indekseret‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (åbner nyt vindue)